Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026 [Yahoo! Financ...
Relay Therapeutics, Inc. (RLAY)
Company Research
Source: Yahoo! Finance
molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that initial clinical results and preclinical data for zovegalisib (RLY-2608) in vascular anomalies will be presented at the International Society for the Study of Vascular Anomalies (ISSVA) World Congress 2026, taking place May 19-22, 2026, in Philadelphia. The company anticipates reporting clinical data on approximately 20 efficacy-evaluable patients. Late Breaking Clinical Abstract: Abstract Title: Initial Results of Zovegalisib (RLY-2608), a Mutant-selective PI3Ka Inhibitor in Adult and Pediatric Patients with PIK3CA-Driven Vascular Malformations Abstract Number: Session: Late Breaking Abstract Session Date/Time: Wednesday, May 20, 4:30 p.m. ET Preclinical Abstract: Abstract Title : Zovegalisib (RLY-2608), a Novel, Mutant-selective, PI3Ka Inhibitor, Induces Lesion Regression, with Minimal Hyperinsulinemia, in Murine M
Show less
Read more
Impact Snapshot
Event Time:
RLAY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLAY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLAY alerts
High impacting Relay Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RLAY
News
- Relay Therapeutics (RLAY) is now covered by JonesTrading. They set a "hold" rating and a $18.00 price target on the stock.MarketBeat
- Relay Therapeutics (RLAY) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Relay Therapeutics (RLAY) had its price target raised by Barclays PLC from $17.00 to $21.00. They now have an "overweight" rating on the stock.MarketBeat
- Relay Therapeutics (RLAY) Surges 16.4%: Is This an Indication of Further Gains? [Yahoo! Finance]Yahoo! Finance
- Relay Therapeutics (RLAY) Is Up 30.6% After Expanding Zovegalisib Into Vascular Anomalies Data Reveal [Yahoo! Finance]Yahoo! Finance
RLAY
Earnings
- 2/26/26 - Beat
RLAY
Sec Filings
- 4/16/26 - Form PRE
- 4/13/26 - Form SCHEDULE
- 4/9/26 - Form 4
- RLAY's page on the SEC website